Systemic corticosteroids are the standard of care for the initial treatment of grade 2–4 GvHD. However, many patients with GvHD do not experience sustained responses to corticosteroids which may lead to multiple organ failure and potential death, and indeed 6-month survival rates among steroid-refractory (SR) patients are approximately 49% with long-term survival rates of only 5–30%.
Post transplantation
GvHD prevalence
GvHD severity
Response to steroids
Systemic corticosteroids are the standard of care for the initial treatment of grade 2–4 GvHD. However, many patients with aGvHD do not experience sustained responses to corticosteroids which may lead to multiple organ failure and potential death, and indeed 6-month survival rates among steroid-refractory (SR) patients are approximately 49% with long-term survival rates of only 5–30%.
AllocetraTM is being developed
to effectively treat steroid-refractory GvHD patients for whom survival forecast is bleak.
Clinical outlook for prevention of post-BMT complications in steroid-refractory patients
Enlivex plans to initiate a Phase II trial during 2020, for the treatment of steroid-refractory GvHD patients.
